KEY BENEFITS AND USES

  • Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
  • Drill down into physicians’ treatment sequences and understand who to position against or how to defend share.
  • Identify untapped treatment scenarios and key competitors to aid trial design.
  • Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
  • Discover untapped populations to expand product share and drive strategic decisions.


QUESTIONS ANSWERED
• Where is my product positioned vs. competitors in the treatment journey?
• What are physicians’ most frequent treatment sequences—who is
benefiting and how can I defend my assets share and position?
• What are the market-relevant treatment scenarios according to oncology
experts?
• Where are the untapped business opportunities that I can capitalize
upon?
• How can I optimize trial design and ensure a competitive edge for my
pipeline asset?

GEOGRAPHIES
United States
PRIMARY MARKET RESEARCH
Survey of ~100 U.S. physicians
2019 COVERAGE
Colorectal Cancer (US)
Multiple Myeloma (US)
Non-Hodgkin's Lymphoma and
Chronic Lymphocytic Leukemia
(US)
Non-Small-Cell Lung Cancer (US)
Ovarian Cancer (US)
Prostate Cancer (US)
Renal Cell Carcinoma (US)


KEY FEATURES

  • Market-relevant treatment scenarios and subpopulations from oncology experts
  • Drug share and treatment rates mapped to treatment journey using physician survey data
  • Physicians’ most frequently selected treatment sequences
  • Access to expert oncology analysts for bespoke support

PRODUCT DESCRIPTION
Treatment Sequencing provides disease-specific, sequential treatment
patterns in market-relevant treatment scenarios and drug share mapped to
treatment journey. The quantitative sequencing analysis illuminates drug
positioning through primary market research-based insights from physicians
and DRG oncology experts’ assumptions.

Table of contents

  • Detailed, Expanded Analysis: Treatment Sequencing (US)
    • Treatment Sequencing Prostate Cancer US June 2019

Author(s): Sudha Malhotra, Ph.D

Sudha Malhotra joined Decision Resource Group in 2018. She is responsible for performing secondary market analysis including patent research, pricing, and clinical trial assessment for major pharmaceutical markets covering a wide range of oncology indications. She obtained her doctorate degree in life sciences from the National Institute of Immunology, New Delhi, India and has authored several original peer-reviewed journal articles. She holds a bachelor’s degree in microbiology and a master’s degree in biomedical sciences both from the University of Delhi, India.


Related Reports

Prostate Cancer | Landscape & Forecast | Disease Landscape & Forecast

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga...

View Details

Prostate Cancer | Current Treatment | Detailed, Expanded Analysis (US)

Hormonal therapies have dominated the treatment of prostate cancer for the past decade. Zytiga (Janssen, generics) and Xtandi (Medivation / Astellas Pharma), initially approved for metastatic cas...

View Details

Prostate Cancer | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key prostate cancer patie...

View Details